US 11,998,633 B2
Topical sol-gel composition for the treatment of dermatitis
Wonkyung Cho, Yongin-si (KR); Kwanghyun Shin, Yongin-si (KR); Joonho Choi, Yongin-si (KR); Kiwha Lee, Yongin-si (KR); Jong Hwa Roh, Yongin-si (KR); Miyoung Park, Yongin-si (KR); Youngho Park, Yongin-si (KR); Eunsil Park, Yongin-si (KR); Jaehong Park, Yongin-si (KR); Byoung Young Woo, Yongin-si (KR); Min Soo Kim, Yongin-si (KR); and Eun Sol Ha, Yongin-si (KR)
Assigned to Amorepacific Corporation, Seoul (KR)
Appl. No. 17/289,382
Filed by Amorepacific Corporation, Seoul (KR)
PCT Filed Oct. 16, 2019, PCT No. PCT/KR2019/013544
§ 371(c)(1), (2) Date Apr. 28, 2021,
PCT Pub. No. WO2020/096217, PCT Pub. Date May 14, 2020.
Claims priority of application No. 10-2018-0136973 (KR), filed on Nov. 9, 2018.
Prior Publication US 2022/0000775 A1, Jan. 6, 2022
Int. Cl. A61K 9/08 (2006.01); A61K 9/06 (2006.01); A61K 31/44 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61K 9/00 (2006.01)
CPC A61K 9/06 (2013.01) [A61K 31/44 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61K 9/0014 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A topical sol-gel composition, comprising
a first component comprising microcrystalline cellulose and carboxymethylcellulose sodium, wherein the first component is contained in an amount of 1 to 10 wt. %, based on the total weight of the topical sol-gel composition;
a second component that is any one selected from the group consisting of hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone vinyl acetate (PVP VA), and a mixture thereof; and
a third component that is any one selected from the group consisting of poloxamer, polysorbate, and a mixture thereof, wherein the third component is contained in an amount of 0.5 to 5 wt. % based on a total weight of the sol-gel composition;
wherein the topical sol-gel composition comprises a polyol,
wherein the topical sol-gel composition comprises a drug, wherein the drug is (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide, and
wherein the topical sol gel composition is a reversible sol gel composition that forms a sol state by application of external physical force, and has a viscosity of 50,000 cps in the gel state and a viscosity of 5,000 cps in the sol state, wherein it takes about 110 min to 120 min for formation of the gel state from the sol state when the sol state is left without application of an external physical force.